|
|
|
|
The linker is key to an antibody-drug conjugate's success, influencing stability and targeted drug release. Explore the evolution of linker chemistry, from cleavable mechanisms to site-specific conjugation, and learn why rigorous assessment is critical.
|
|
|
|
|
This case study highlights a successful collaboration that enabled the design and development of novel, cell-permeable maytansine-based payloads for ADCs, featuring newly engineered tubulin inhibitors optimized to enhance the critical “bystander killer effect.”
|
|
|
|
|
In this webinar, our experts discuss how to develop lower-risk strategies by examining the key considerations for conjugating linker payloads to antibodies, including a review of the advantages and limitations of semi-synthetic and synthetic approaches.
|
|
|
|
|
The success of an ADC hinges on the quality and stability of its linker-payload construct. Here, we explain why custom synthesis of these complex molecules requires an efficient, integrated approach in order to accelerate a drug discovery and development timeline.
|
|
|
|
|
|
|
In this on-demand presentation, discover how our integrated expertise can help you develop and manufacture dual payload ADCs with optimized efficacy, precision conjugation, and scalable solutions.
|
|
|
|
|
|
|
